Author Description

Covering all key topics of radiolabelled antibodies for targeted radiotherapy (RIT) of cancer, this study includes chapters on: radionuclide properties and their selection for RIT; in vivo dosimetry; novel forms of antibodies designed for tumour targeting; and new approaches to improving targeting and treatment of solid tumours and lymphomas with RIT.